We are live on ! Find out more
LCM

Laurion Capital Management Portfolio holdings

AUM $2.29B
1-Year Est. Return 75.73%
This Fund
S&P 500
This Quarter Est. Return
+6.97%
1 Year Est. Return
+75.73%
3 Year Est. Return
+162.63%
5 Year Est. Return
+130.38%
10 Year Est. Return
+388.8%
AUM
$17.9B
AUM Growth
+$3.18B
Cap. Flow
+$2.11B
Cap. Flow %
11.82%
Top 10 Hldgs %
38.29%
Holding
721
New
293
Increased
98
Reduced
124
Closed
140

Top Buys

Rank Stock Value
1
TMUS icon
T-Mobile US
TMUS
+$124M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$95.2M
3
PLRX icon
Pliant Therapeutics
PLRX
+$74.8M
4
MSFT icon
Microsoft
MSFT
+$72.6M
5
BMY icon
Bristol-Myers Squibb
BMY
+$56.6M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$123M
2
CTLT
CATALENT, INC.
CTLT
+$60.4M
3
EMR icon
Emerson Electric
EMR
+$55M
4
HD icon
Home Depot
HD
+$54.8M
5
CMCSA icon
Comcast
CMCSA
+$53.9M

Sector Composition

Rank Sector Weight
1 Healthcare 5.44%
2 Technology 2.51%
3 Communication Services 1.69%
4 Utilities 1.38%
5 Industrials 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VZ icon
701
CALL
Verizon
VZ
$196B
– –
-745,700
Closed -$29M
WBA
702
CALL
DELISTED
Walgreens Boots Alliance
WBA
– –
-724,200
Closed -$25M
WM icon
703
Waste Management
WM
$91B
– –
-31,181
Closed -$5.09M
WW
704
DELISTED
WW International
WW
– –
-12,222
Closed -$50.4K
YMM icon
705
Full Truck Alliance
YMM
$9.99B
– –
-133,048
Closed -$1.01M
ZVRA icon
706
Zevra Therapeutics
ZVRA
$686M
– –
-571,200
Closed -$3.14M
PSTX
707
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
– –
-545,700
Closed -$1.68M
CTLT
708
DELISTED
CATALENT, INC.
CTLT
– –
-919,854
Closed -$60.4M
PWSC
709
DELISTED
PowerSchool Holdings, Inc.
PWSC
– –
-300,000
Closed -$5.95M
RAIN
710
DELISTED
Rain Oncology Inc. Common Stock
RAIN
– –
-313,200
Closed -$2.74M
NATI
711
DELISTED
National Instruments Corp
NATI
– –
-323,328
Closed -$16.9M
ISEE
712
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-50,805
Closed -$1.24M
BLU
713
DELISTED
BELLUS Health Inc.
BLU
– –
-4,833,580
Closed -$34.8M
RXDX
714
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-195,663
Closed -$21M
FNCH
715
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
– –
-1,933
Closed -$22.8K
DMYS.WS
716
DELISTED
dMY Technology Group, Inc. VI Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share
DMYS.WS
– –
-25,000
Closed -$1.99K
DMYS
717
DELISTED
dMY Technology Group, Inc. VI
DMYS
– –
-50,000
Closed -$511K
CDAK
718
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
– –
-2,013,300
Closed -$351K
MBAC.U
719
DELISTED
M3-Brigade Acquisition II Corp. Units, each consisting of one share of Class A common stock, and one-third of one redeemable warrant
MBAC.U
– –
-400,000
Closed -$4.04M
25 26 27 28
29

Similar funds

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return
GCP
Greenoaks Capital Partners Orinda, California $2.3B AUM 19.87% 1-Year Est. Return
LCM
Logan Capital Management Newtown Square, Pennsylvania $2.3B AUM 30.85% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
MA
MCF Advisors Covington, Kentucky $2.28B AUM 14.87% 1-Year Est. Return
LFM
LGT Fund Management Vaduz, Liechtenstein $2.3B AUM 22.66% 1-Year Est. Return
NSAM
North Star Asset Management Neenah, Wisconsin $2.31B AUM 10.09% 1-Year Est. Return
ABI
Abrams Bison Investments Bethesda, Maryland $2.31B AUM 40.26% 1-Year Est. Return

Laurion Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Laurion Capital Management held 721 positions worth $17.9B, up 22% from $14.7B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Laurion Capital Management deployed $2.11B of net new capital in Q2 2023, opening 293 new positions and adding to 98 existing holdings. Its largest new stake was Pliant Therapeutics: 3,158,570 shares worth $57.2M.

By sector, the portfolio is most concentrated in Healthcare at 5.4% of assets, down from 6.6% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Viatris, an estimated $123M trimmed.

  • Laurion Capital Management's largest Q2 2023 buy was Pliant Therapeutics: 3,158,570 shares worth $57.2M.
  • Laurion Capital Management added most to T-Mobile US in Q2 2023, an estimated $124M increase.
  • Laurion Capital Management's biggest Q2 2023 reduction was Viatris, cutting an estimated $123M.
  • Laurion Capital Management fully exited CATALENT, INC. in Q2 2023, selling an estimated $60.4M.
  • Laurion Capital Management's ten largest holdings make up 38% of its $17.9B portfolio in Q2 2023.
  • Laurion Capital Management opened 293 new positions and closed 140 in Q2 2023.
  • Laurion Capital Management's portfolio value rose 22% quarter-over-quarter to $17.9B.

Based on Laurion Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.